Improving cancer treatment with light-activated drugs
Optimizing Protic Ruthenium Anticancer Compounds for Singlet Oxygen Production and Enhanced Photocytotoxicity
This study is exploring new light-activated drugs designed to target and kill bladder cancer cells while leaving healthy cells unharmed, which could lead to better and safer treatment options for patients.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama in Tuscaloosa NIH-funded |
| Lab location | 1 site (Tuscaloosa, United States) |
| Project ID | NIH-10579670 on NIH RePORTER |
What this research studies
This research focuses on developing new light-activated drugs that specifically target cancer cells, particularly bladder cancer. By using a technique called photodynamic therapy, these drugs can be activated by light to produce toxic agents that selectively kill cancer cells while sparing healthy ones. The study involves synthesizing and testing various compounds to find the most effective ones for this purpose. Patients may benefit from more effective and less harmful cancer treatments if these new drugs prove successful.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with bladder cancer who are seeking innovative treatment options.
Not a fit: Patients with non-cancerous conditions or those who do not have bladder cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for bladder cancer with fewer side effects.
How similar studies have performed: Previous studies have shown promise with similar light-activated therapies, indicating potential for success in this approach.
Where this research is happening
Tuscaloosa, United States
- University of Alabama in Tuscaloosa — Tuscaloosa, United States (Active)
Researchers
- Principal investigator: Papish, Elizabeth Tabitha — University of Alabama in Tuscaloosa
- Study coordinator: Papish, Elizabeth Tabitha
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.